Proglumide as a Morphine Adjunct in Cancer Pain Management

Slides:

Advertisements

Similar presentations

Using a Morphine Equivalence Metric to Quantify Opioid Consumption: Examining the Capacity to Provide Effective Treatment of Debilitating Pain at the Global,

Advertisements

The Relationship Between Depression and Pain Language in Cancer and Chronic Non- Cancer Pain Patients Thomas C. Sist, DDS, Gerard A. Florio, PhD, Marguerite.

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

The Treatment of Chronic Cancer Pain in a Cancer Hospital in the Netherlands Rianne de Wit, MS, Frits van Dam, PhD, Ans Vielvoye-Kerkmeer, PhD, Carlien.

Steven J. Linton, Alan E. Fruzzetti Scandinavian Journal of Pain

Safety, Tolerability and Symptom Outcomes Associated with l-Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase.

One-Year rTMS Treatment for Refractory Trigeminal Neuralgia

Managing Cancer Pain: Basic Principles and Invasive Treatments

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

An Assessment of the Safety, Eff icacy, and Acceptability of Intranasal Fentanyl Citrate in the Management of Cancer-Related Breakthrough Pain Giovambattista.

A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain Richard L. Rauck, MD, Mark S. Wallace,

An Effective Treatment of Severe Complex Regional Pain Syndrome Type 1 in a Child Using High Doses of Intrathecal Ziconotide Michael Stanton-Hicks, MD,

Pain during bone marrow aspiration: prevalence and prevention

Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis Paolo Vercellini, M.D., Giussy Barbara, M.D., Edgardo Somigliana,

Analgesic and Sedative Effects of Melatonin in Temporomandibular Disorders: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study Liliane.

Edmonton, Canada: A Regional Model of Palliative Care Development

Pain Severity in Diabetic Peripheral Neuropathy is Associated with Patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep Mugdha Gore,

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine Rainer Sabatowski, MD, Stefan.

Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced Cancer Alfredo H. Navigante, MD, PhD,

Samy A. Alsirafy, MBBCh, MSc, MD, ABHPM, Dip Pall Med

Bettina N. Nielsen, MSc, Gitte Aagaard, RN, Steen W

Eduardo Bruera, MD, Raul Sala, MD, Odette Spruyt, MD, J

Individual Difference Variables and the Effects of Progressive Muscle Relaxation and Analgesic Imagery Interventions on Cancer Pain Kristine L. Kwekkeboom,

Advances in Rheumatology

One-Year rTMS Treatment for Refractory Trigeminal Neuralgia

Transdermal Fentanyl for Chronic Pain in AIDS

David Clark, PhD, Michael Wright, PhD

Differences in the Prevalence and Severity of Side Effects Based on Type of Analgesic Prescription in Patients with Chronic Cancer Pain Patrice Villars,

Long-Term Analgesic Effects of Transcranial Direct Current Stimulation of the Motor Cortex on Phantom Limb and Stump Pain: A Case Report Nadia Bolognini,

Treatment of Cancer Pain with Noninvasive Brain Stimulation

Development of a Cancer Pain Prognostic Scale

Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study Kim Fisher, PhD, Carla Stiles,

Jodi L. Hannan, MD, Steven M. Radwany, MD, Terry Albanese, PhD

Suresh K Joishy, MD, FACP, Declan Walsh, MSc, FACP

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

A Pilot Exploration of the Antiemetic Activity of Olanzapine for the Relief of Nausea in Patients with Advanced Cancer and Pain Steven D. Passik, PhD,

The Role of Patients' Expectations in the Development of Anticipatory Nausea Related to Chemotherapy for Cancer Jane T. Hickok, MD, MPH, Joseph A. Roscoe,

Abuse Potential of Morphine/Dextromethorphan Combinations

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

The Pro-Self© Pain Control Program Improves Patients' Knowledge of Cancer Pain Management Tone Rustøen, RN, PhD, Berit Taraldsen Valeberg, RN, PhD, Eva.

Strategies in Pain Management

Improving Access to Opioid Analgesics for Palliative Care in India

Assessing Pain and Mood in a Poorly Resourced Country in a Post-Conflict Setting Amanda C. de C. Williams, BSc, MSc, PhD, Minha Rajput-Ray, BSc, Ost Med,

Changing M3G/M6G Ratios and Pharmacodynamics in a Cancer Patient During Long- Term Morphine Treatment Gertrud Andersen, MD, Lona L Christrup, PhD, Per.

Drug Infusors in Palliative Medicine

The COX-2 Specific Inhibitor, Valdecoxib, Is An Effective, Opioid-Sparing Analgesic in Patients Undergoing Total Knee Arthroplasty Lowell W Reynolds,

The Impact of Symptoms, Coping Capacity, and Social Support on Quality of Life Experience Over Time in Patients with Lung Cancer Ingela Henoch, RN, PhD,

Cancer Pain Education Journal of Pain and Symptom Management

Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness—An Exploratory Study Diana H. Ferreira,

No evidence for sex differences in the severity and treatment of cancer pain Janet M. Edrington, RN, MS, Steven Paul, PhD, Marylin Dodd, RN, PhD, Claudia.

Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu,

Gertrud Andersen, MD, Lona Christrup, PhD, Per Sjøgren, MD

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate- Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two.

A Scale for Measuring Patient Perceptions of the Quality of End-of-Life Care and Satisfaction with Treatment Daniel P. Sulmasy, OFM, MD, PhD, Jessica.

Clinical and Economic Impact of Palliative Care Consultation

Knowledge and Attitudes of Italian Medical Staff Towards the Approach and Treatment of Patients in Pain Marco Visentin, MD, Leonardo Trentin, MD, Roberto.

Iontophoretic Vincristine in the Treatment of Postherpetic Neuralgia

Beyond Intuition: Patient Fever Symptom Experience

A Titrated Morphine Analgesic Regimen Comparing Substance Users and Non-Users with AIDS-Related Pain Ronald Kaplan, MD, Joseph Slywka, PhD, Susan Slagle,

Physical Function in Patients with Cancer

Safety, Tolerability and Symptom Outcomes Associated with l-Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase.

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

Longitudinal Documentation of Cancer Pain Management Outcomes

Multidimensional independent predictors of cancer-related fatigue

Managing Cancer Pain: Basic Principles and Invasive Treatments

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

Depomedroxyprogesterone Acetate for Hot Flashes

Use of Pregabalin in the Management of Chronic Uremic Pruritus

Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life Ariel Berger, MPH, Ellen Dukes, PhD, RN, Meredith.

Presentation transcript:

Proglumide as a Morphine Adjunct in Cancer Pain Management Zale P. Bernstein, MD, Steven Yucht, MD, Ellen Battista, RN, MS, Mark Lema, MD, PhD, Monica B. Spaulding, MD Journal of Pain and Symptom Management Volume 15, Issue 5, Pages 314-320 (May 1998) DOI: 10.1016/S0885-3924(98)00003-7

Fig. 1. Schema of proglumide study. *Indicates first scheduled analgesic post 6 a.m. and 12 noon, respectively Journal of Pain and Symptom Management 1998 15, 314-320DOI: (10.1016/S0885-3924(98)00003-7)

Fig. 2. Visual analog scale; one of five visual analog scale descriptors used—please see text Journal of Pain and Symptom Management 1998 15, 314-320DOI: (10.1016/S0885-3924(98)00003-7)

Fig. 3. Visual analogue scale pain descriptors—results of treatment arms and baseline for time of day and post-treatment testing times. PRO, one-half usual analgesic dose plus Proglumide; PLA, full usual analgesic dose plus placebo; and BAS, baseline (full) analgesic dose prior to study, respectively. *Significant differences between treatment arms, all other responses statistically equivalent for all other descriptors Journal of Pain and Symptom Management 1998 15, 314-320DOI: (10.1016/S0885-3924(98)00003-7)

Fig. 4. Tursky verbal rating scale descriptors—results of treatment arms and baseline for times of day and post-treatment testing times. PRO, PLA, and BAS refer to one-half usual analgesic dose plus Proglumide, full usual analgesic dose plus placebo and baseline (full) analgesic dose prior to study, respectively. All responses statistically equivalent for all descriptors. For derivation of mean verbal scores, see text Journal of Pain and Symptom Management 1998 15, 314-320DOI: (10.1016/S0885-3924(98)00003-7)